Sunshine Biopharma (SBFM) FCF Margin (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly FCF Margin came in at 9.99% in Q2 2026, up 525.0% on a YoY basis from 1.6% in Q2 2025, and up 61.12% quarter-over-quarter from 25.68% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) FCF Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported FCF Margin for 10 consecutive years, with 9.99% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 525.0% year-over-year to 9.99%; the trailing twelve-month figure through Jun 2026 stood at 15.2% (up 824.0% YoY), and the FY2025 full-year result was 15.16%, up 2550.0% from the prior year.
- FCF Margin advanced to 9.99% in Q2 2026 per SBFM's latest filing, from 25.68% in the prior quarter.
- Across five years, FCF Margin topped out at 7.84% in Q3 2023 and bottomed at 1063.4% in Q1 2022.
- Historically, FCF Margin has averaged 153.07% across 5 years, with a median of 33.3% in 2023.
- The sharpest annual moves came in 2022 and 2023: FCF Margin sank 32109 bps in 2022, then surged 102560 bps in 2023.
- Over 5 years, FCF Margin stood at 61.95% in 2022, then soared by 52 bps to 30.04% in 2023, then fell by 22 bps to 36.56% in 2024, then jumped by 48 bps to 18.83% in 2025, then jumped by 47 bps to 9.99% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 9.99%, 25.68%, and 18.83% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 7.41% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 8.76% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 3.10% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -6.52% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 20.79% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 14.76% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 20.15% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 23.24% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | -9.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.99% |
| Mar 31, 2026 | -25.68% |
| Dec 31, 2025 | -18.83% |
| Sep 30, 2025 | -8.01% |
| Jun 30, 2025 | -15.23% |
| Mar 31, 2025 | -19.13% |
| Dec 31, 2024 | -36.56% |
| Sep 30, 2024 | -22.21% |
| Jun 30, 2024 | -59.68% |
| Mar 31, 2024 | -43.07% |
| Dec 31, 2023 | -30.04% |
| Sep 30, 2023 | -7.84% |
| Jun 30, 2023 | -67.94% |
| Mar 31, 2023 | -37.80% |
| Dec 31, 2022 | -61.95% |
| Sep 30, 2022 | -846.14% |
| Jun 30, 2022 | -381.75% |
| Mar 31, 2022 | -1,063.40% |
| Dec 31, 2021 | -366.68% |
| Sep 30, 2021 | -1,192.65% |